



Attorney Docket No. VPI/02-116 US  
*[Handwritten signature]*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/700,333  
Confirmation No.: 5159  
Filing Date: November 3, 2003  
Examiner: Venkataraman Balasubramanian  
Group Art Unit: 1624  
Applicants: Mark Ledeboer et al.  
For: COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES

July 21, 2006  
Cambridge, Massachusetts

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER FOR SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

(a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.

Copies of references Citation Nos. A2; B8-B12 are attached.

Copy(ies) of references Citation No(s). \_\_\_\_\_ was/were filed in application U.S. Application No(s). \_\_\_\_\_ filed \_\_\_\_\_, from which this application claims priority under 35 U.S.C. § 120.

A copy of the International Search Report received in the corresponding PCT Application No. \_\_\_\_\_ is attached herewith.

(b)  No fee is believed due because:

The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.

The Information Disclosure Statement is being concurrently filed with the above-identified application.

The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).

- The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.
- (c)  The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
  - Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
  - No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
  - The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- (d)  The Information Disclosure Statement is being filed on or before the payment of the issue fee; and
  - Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
  - No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
  - The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Applicants: Mark Ledeboer et al.  
Application No.: 10/700,333

Respectfully submitted,

Karen E. Brown  
Karen E. Brown, Reg. No. 43,866  
Attorney for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6168  
Fax: (617) 444-6483  
Customer No.: 27916

I hereby certify that this correspondence and any documents referred to as attached hereto are being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to:  
Mail Stop Amendment, Commissioner for Patents,  
P.O. Box 1450, Alexandria, VA 22313-1450 on July 21, 2006

Lisa M. Romano  
\_\_\_\_\_  
\_\_\_\_\_  
Signature



Modified Form 1449/PTO

 SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/700,333
Filing Date	November 3, 2003
First Named Inventor	Mark Ledeboer
Group Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VPI/02-116 US

## U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date/ Publication Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A2	6,949,544	September 27, 2005	Vertex Pharmaceuticals Incorporated	514	235.8	March 28, 2002

## FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Office	Patent Document Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B8	WO	02/22601	Vertex Pharmaceuticals Incorporated	21 March 2002	
	B9	WO	99/65897	Chiron Corporation	23 December 1999	
	B10	WO	95/09851	Ciba-Geigy AG	13 April 1995	
	B11	WO	95/09847	Ciba-Geigy AG	13 April 1995	
	B12	WO	95/09853	Ciba-Geigy AG	13 April 1995	

## OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.